|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Venook AP, Papandreou C, Furuse J and de
Guevara LL: The incidence and epidemiology of hepatocellular
carcinoma: A global and regional perspective. Oncologist. 15 Suppl
4:S5–S13. 2010. View Article : Google Scholar
|
|
3
|
Lau WY and Lai EC: Hepatocellular
carcinoma: Current management and recent advances. Hepatobiliary
Pancreat Dis Int. 7:237–257. 2008.PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pillai RS: MicroRNA function: Multiple
mechanisms for a tiny RNA? RNA. 11:1753–1761. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hayes J, Peruzzi PP and Lawler S:
MicroRNAs in cancer: Biomarkers, functions and therapy. Trends Mol
Med. 20:460–469. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mao B and Wang G: MicroRNAs involved with
hepatocellular carcinoma (Review). Oncol Rep. 34:2811–2820. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giordano S and Columbano A: MicroRNAs: New
tools for diagnosis, prognosis, and therapy in hepatocellular
carcinoma? Hepatology. 57:840–847. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu Q, Zhang F, Du Z and Xiang Y:
Up-regulation of serum miR-744 predicts poor prognosis in patients
with nasopharyngeal carcinoma. Int J Clin Exp Med. 8:13296–13302.
2015.PubMed/NCBI
|
|
10
|
Zhou W, Li Y, Gou S, Xiong J, Wu H, Wang
C, Yan H and Liu T: MiR-744 increases tumorigenicity of pancreatic
cancer by activating Wnt/beta-catenin pathway. Oncotarget.
6:37557–37569. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fang Y, Zhu X, Wang J, Li N, Li D, Sakib
N, Sha Z and Song W: MiR-744 functions as a proto-oncogene in
nasopharyngeal carcinoma progression and metastasis via
transcriptional control of ARHGAP5. Oncotarget. 6:13164–13175.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Vislovukh A, Kratassiouk G, Porto E,
Gralievska N, Beldiman C, Pinna G, El'skaya A, Harel-Bellan A,
Negrutskii B and Groisman I: Proto-oncogenic isoform A2 of
eukaryotic translation elongation factor eEF1 is a target of
miR-663 and miR-744. Br J Cancer. 108:2304–2311. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guan H, Liu C, Fang F, Huang Y, Tao T,
Ling Z, You Z, Han X, Chen S, Xu B and Chen M: MicroRNA-744
promotes prostate cancer progression through aberrantly activating
Wnt/beta-catenin signaling. Oncotarget. 8:14693–14707. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen XF and Liu Y: MicroRNA-744 inhibited
cervical cancer growth and progression through apoptosis induction
by regulating Bcl-2. Biomed Pharmacother. 81:379–387. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tan YL, Bai ZG, Zou WL, Ma XM, Wang TT,
Guo W, Liu J, Li JS, Jie Yin, Zang YJ, et al: miR-744 is a
potential prognostic marker in patients with hepatocellular
carcinoma. Clin Res Hepatol Gastroenterol. 39:359–365. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lin F, Ding R, Zheng S, Xing D, Hong W,
Zhou Z and Shen J: Decrease expression of microRNA-744 promotes
cell proliferation by targeting c-Myc in human hepatocellular
carcinoma. Cancer Cell Int. 14:582014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ding H, Quan H, Yan W and Han J: Silencing
of SOX12 by shRNA suppresses migration, invasion and proliferation
of breast cancer cells. Biosci Rep. 36:e003892016. View Article : Google Scholar :
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu Y, Zhang W, Liu S, Liu K, Ji B and
Wang Y: miR-365 targets ADAM10 and suppresses the cell growth and
metastasis of hepatocellular carcinoma. Oncol Rep. 37:1857–1864.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Huang JT, Liu SM, Ma H, Yang Y, Zhang X,
Sun H, Zhang X, Xu J and Wang J: Systematic review and
meta-analysis: Circulating miRNAs for diagnosis of hepatocellular
carcinoma. J Cell Physiol. 231:328–335. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Khare S, Zhang Q and Ibdah JA: Epigenetics
of hepatocellular carcinoma: Role of microRNA. World J
Gastroenterol. 19:5439–5445. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nurul-Syakima AM, Yoke-Kqueen C, Sabariah
AR, Shiran MS, Singh A and Learn-Han L: Differential microRNA
expression and identification of putative miRNA targets and
pathways in head and neck cancers. Int J Mol Med. 28:327–336.
2011.PubMed/NCBI
|
|
24
|
Sha Z, Zhu X, Li N, Li Y and Li D:
Proto-oncogenic miR-744 is upregulated by transcription factor
c-Jun via a promoter activation mechanism. Oncotarget.
7:64977–64986. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hoser M, Potzner MR, Koch JM, Bosl MR,
Wegner M and Sock E: Sox12 deletion in the mouse reveals
nonreciprocal redundancy with the related Sox4 and Sox11
transcription factors. Mol Cell Biol. 28:4675–4687. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang W, Chen Z, Shang X, Tian D, Wang D,
Wu K, Fan D and Xia L: Sox12, a direct target of FoxQ1, promotes
hepatocellular carcinoma metastasis through up-regulating Twist1
and FGFBP1. Hepatology. 61:1920–1933. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jiang T, Guan LY, Ye YS, Liu HY and Li R:
MiR-874 inhibits metastasis and epithelial-mesenchymal transition
in hepatocellular carcinoma by targeting SOX12. Am J Cancer Res.
7:1310–1321. 2017.PubMed/NCBI
|
